Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aurinia Pharm Ord (AUPH)

Aurinia Pharm Ord (AUPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,059,356
  • Shares Outstanding, K 131,841
  • Annual Sales, $ 235,130 K
  • Annual Income, $ 5,750 K
  • EBIT $ 80 M
  • EBITDA $ 100 M
  • 60-Month Beta 1.42
  • Price/Sales 8.58
  • Price/Cash Flow 49.64
  • Price/Book 5.52

Options Overview Details

View History
  • Implied Volatility 50.51% (+1.88%)
  • Historical Volatility 49.69%
  • IV Percentile 32%
  • IV Rank 20.40%
  • IV High 135.37% on 11/24/25
  • IV Low 28.76% on 08/20/25
  • Expected Move (DTE 11) 1.11 (7.07%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 415
  • Volume Avg (30-Day) 756
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 33,927
  • Open Int (30-Day) 34,074
  • Expected Range 14.52 to 16.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.21
  • Number of Estimates 3
  • High Estimate 0.25
  • Low Estimate 0.18
  • Prior Year 0.09
  • Growth Rate Est. (year over year) +133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.94 +12.09%
on 11/06/25
16.48 -5.22%
on 11/26/25
+1.17 (+8.10%)
since 11/05/25
3-Month
10.34 +51.06%
on 09/29/25
16.48 -5.22%
on 11/26/25
+3.22 (+25.97%)
since 09/05/25
52-Week
6.55 +138.47%
on 02/27/25
16.48 -5.22%
on 11/26/25
+6.74 (+75.90%)
since 12/05/24

Most Recent Stories

More News
Aurinia: Q3 Earnings Snapshot

Aurinia: Q3 Earnings Snapshot

AUPH : 15.62 (+2.02%)
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

Third Quarter 2025 LUPKYNIS Sales Grew 27% LUPKYNIS Sales Guidance for 2025 Raised to $265 Million to $270 Million Aritinercept Advances...

AUPH : 15.62 (+2.02%)
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress...

AUPH : 15.62 (+2.02%)
Aurinia Pharmaceuticals to Present New LUPKYNIS Data at Key Conferences

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aurinia Pharmaceuticals...

AUPH : 15.62 (+2.02%)
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS ® (voclosporin)...

AUPH : 15.62 (+2.02%)
Aurinia Responds to Now Retracted LinkedIn Post

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today responded to a now retracted LinkedIn post referencing voclosporin by an FDA official. Aurinia stands behind the favorable benefit/risk...

AUPH : 15.62 (+2.02%)
Aurinia: Q2 Earnings Snapshot

Aurinia: Q2 Earnings Snapshot

AUPH : 15.62 (+2.02%)
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2025. Financial Results ...

AUPH : 15.62 (+2.02%)
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release second quarter 2025 financial and operational results before markets open on July 31, 2025. ...

AUPH : 15.62 (+2.02%)
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options

Investors in Aurinia Pharmaceuticals Inc. AUPH need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $2.00 Call had some of the highest...

AUPH : 15.62 (+2.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

3rd Resistance Point 16.52
2nd Resistance Point 16.08
1st Resistance Point 15.85
Last Price 15.62
1st Support Level 15.18
2nd Support Level 14.75
3rd Support Level 14.52

See More

52-Week High 16.48
Last Price 15.62
Fibonacci 61.8% 12.69
Fibonacci 50% 11.51
Fibonacci 38.2% 10.34
52-Week Low 6.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar